menu
    • menu
    [{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois Chicago","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTC-352","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ University of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University of Illinois Chicago"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ University of Illinois","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University of Illinois"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ Lantern Pharma","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ Lantern Pharma"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lantern Pharma \/ TTC Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ TTC Oncology"}]

    Find Clinical Drug Pipeline Developments & Deals for TTC-352

    Menu

    TTC-352

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lantern Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Lantern Pharma

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : TTC Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TTC Oncology LLC Signs a Collaboration Agreement With Lantern Pharma

                            Details : Lantern Pharma is receiving an exclusive right to license TTC-352, an orally available, first-in-class selective human ER partial agonist and small molecule being developed as a treatment for patients with metastatic estrogen receptor-positive breast can...

                            Brand Name : TTC-352

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : TTC Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TTC Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            TTC Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lantern Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidat...

                            Details : The collaboration will focus on leveraging RADR® AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations potentially identified by RADR®.

                            Brand Name : TTC-352

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 27, 2023

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lantern Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TTC Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            TTC Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of Illinois

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TTC Oncology Launches Equity Crowdfunding Campaign on WeFunder to Support Funding of Phase 2 Clinical Trials f...

                            Details : Launching of equity crowdfunding campaign, which is providing bridge financing for phase 2 clinical trial. The trial will include validation of biomarker that would predict benefit from TTC-352 therapy.

                            Brand Name : TTC-352

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 20, 2021

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of Illinois

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TTC Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            TTC Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of Illinois Chicago

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase 1 Human Trials Suggest Uic-Developed Breast Cancer Drug Is Safe, Effective

                            Details : Preclinical studies showed that TTC-352, which is a selective human estrogen receptor partial agonist, causes complete tumor regression, but unlike tamoxifen, may pose a reduced risk of uterine cancer development.

                            Brand Name : TTC-352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 27, 2020

                            Lead Product(s) : TTC-352

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of Illinois Chicago

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth